We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+10.14%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$116M
AUM Growth
+$19.2M
Cap. Flow
+$6.29M
Cap. Flow %
5.4%
Top 10 Hldgs %
65.75%
Holding
56
New
8
Increased
9
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
AMPE
Ampio Pharmaceuticals Inc.
AMPE
+$9.46M
2
DSCI
Derma Sciences, Inc. Common Stock (DE)
DSCI
+$4.24M
3
GLMD icon
Galmed Pharmaceuticals
GLMD
+$2.63M
4
ATRC icon
AtriCure
ATRC
+$2.34M
5
VXRT
Vaxart
VXRT
+$2.26M

Top Sells

Rank Stock Value
1
GIVN
GIVEN IMAGING LTD
GIVN
+$4.7M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.56M
3
STXS icon
Stereotaxis
STXS
+$1.74M
4
RIOT icon
Riot Platforms
RIOT
+$1.33M
5
ACHV icon
Achieve Life Sciences
ACHV
+$928K

Sector Composition

Rank Sector Weight
1 Healthcare 70.62%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
DELISTED
Clovis Oncology, Inc.
CLVS
$873K 0.75%
12,600
– –
DMK
27
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$795K 0.68%
1,786
– –
CYTR
28
DELISTED
CytRx Corp
CYTR
$785K 0.67%
+37,500
New +$1.33M
EXAC
29
DELISTED
Exactech Inc
EXAC
$713K 0.61%
31,636
– –
IMUC
30
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$691K 0.59%
+14,167
New +$693K
SRGA
31
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$682K 0.59%
5,569
– –
OCRX
32
DELISTED
Ocera Therapeutics, Inc.
OCRX
$667K 0.57%
63,223
– –
ICPT
33
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$660K 0.57%
2,000
-7,598
-79% -$2.56M
APEN
34
DELISTED
Apollo Endosurgery, Inc.
APEN
$499K 0.43%
+1,364
New +$495K
MASI
35
DELISTED
Masimo
MASI
$478K 0.41%
17,500
– –
CRIS icon
36
Curis
CRIS
$9.67M
$423K 0.36%
75
– –
AVEO
37
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$391K 0.34%
+26,151
New +$470K
AKTX
38
Akari Therapeutics
AKTX
$14M
$285K 0.25%
+5
New +$283K
GNVC
39
DELISTED
GenVec, Inc.
GNVC
$265K 0.23%
+10,000
New +$326K
TNXP icon
40
Tonix Pharmaceuticals
TNXP
$161M
– –
0
– –
RIOT icon
41
Riot Platforms
RIOT
$8.36B
$192K 0.17%
9,125
-64,625
-88% -$1.33M
CEMI
42
DELISTED
Chembio diagnostics, Inc.
CEMI
$190K 0.16%
55,202
– –
ARCT icon
43
Arcturus Therapeutics
ARCT
$168M
$175K 0.15%
+1,374
New +$204K
RVP icon
44
Retractable Technologies
RVP
$20.1M
$76K 0.07%
20,000
– –
ACHV icon
45
Achieve Life Sciences
ACHV
$647M
– –
-51
Closed -$928K
DVAX
46
DELISTED
Dynavax Technologies
DVAX
– –
-29,000
Closed -$568K
PTN
47
Palatin Technologies
PTN
$13.9M
– –
-276
Closed -$253K
TGTX icon
48
TG Therapeutics
TGTX
$8.19B
– –
-75,000
Closed -$293K
TOVX icon
49
Theriva Biologics
TOVX
$9.64M
– –
-21
Closed -$283K
HSTO
50
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-678
Closed -$875K
1
2
3

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return

DAFNA Capital Management's Q1 2014 Portfolio in Review

As of Q1 2014, DAFNA Capital Management held 56 positions worth $116M, up 20% from $97.2M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

DAFNA Capital Management deployed $6.29M of net new capital in Q1 2014, opening 8 new positions and adding to 9 existing holdings. Its largest new stake was Galmed Pharmaceuticals: 1,123 shares worth $2.32M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 57% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Intercept Pharmaceuticals, Inc., an estimated $2.56M trimmed.

  • DAFNA Capital Management's largest Q1 2014 buy was Galmed Pharmaceuticals: 1,123 shares worth $2.32M.
  • DAFNA Capital Management added most to Ampio Pharmaceuticals Inc. in Q1 2014, an estimated $9.46M increase.
  • DAFNA Capital Management's biggest Q1 2014 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $2.56M.
  • DAFNA Capital Management fully exited GIVEN IMAGING LTD in Q1 2014, selling an estimated $4.7M.
  • DAFNA Capital Management's ten largest holdings make up 66% of its $116M portfolio in Q1 2014.
  • DAFNA Capital Management opened 8 new positions and closed 10 in Q1 2014.
  • DAFNA Capital Management's portfolio value rose 20% quarter-over-quarter to $116M.

Based on DAFNA Capital Management's 13F filing for Q1 2014, filed 15 May 2014.